Supplementary Data S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Aina Oliver‐Caldés; Marta Español‐Rego; Aintzane Zabaleta; Verónica González‐Calle; Sergio Navarro‐Velázquez; Susana Inogès; Ascensión López‐Díaz de Cerio; Valentín Cabañas; Nieves López‐Muñoz; Paula Rodríguez‐Otero; Juan Luis Reguera; David F. Moreno; Núria Martínez‐Cibrián; Lucía López‐Corral; Lorena Pérez-Amill; Beatriz Martín-Antonio; Laura Rosiñol; Joan Cid; Natalia Tovar; Joaquín Sáez‐Peñataro; Miriam López-Parra; Eulàlia Olesti; Elena Guillén; Sara Varea; Luis Gerardo Rodríguez‐Lobato; Anthony M. Battram; Marta Sonia González; Andrés Sánchez‐Salinas; Europa Azucena González‐Navarro; Valentín Ortiz‐Maldonado; Julio Delgado; Felipe Prósper; Manel Juan; Joaquín Martínez‐López; José M. Moraleda; María‐Victoria Mateos; Álvaro Urbano-Ispizúa; Bruno Paiva; Mariona Pascal; Carlos Fernández de Larrea

doi:10.1158/1078-0432.25826741.v1

May 15, 2024Open Access

Supplementary Data S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Share

Key Points

Efficacy and safety data are being assessed for the BCMA-CART therapy in treating multiple myeloma.
The study protocol focuses on determining specific biomarkers indicative of treatment success.
This analysis uses a detailed methodology tailored for evaluating the BCMA-CART intervention in a clinical setting, emphasizing biomarker relevance in outcomes during assessment phases. Supporting future directions in multiple myeloma treatment, this protocol may enable personalized therapies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Study protocol outlines biomarker assessment of BCMA-CART treatment's efficacy and safety in refractory multiple myeloma, suggesting future clinical directions.

Abstract

Summary of the Study Protocol

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oliver‐Caldés et al. (2024) studied this question.

synapsesocial.com/papers/68e6a13db6db643587624d52 https://doi.org/10.1158/1078-0432.25826741.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Data S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Data S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers